Session Title: Virtual Poster Hall
Session Time: None. Available on demand.
Disclosures: Lynne F. Turner Stokes, DM, FRCP: Ipsen (Products/Services: Yes) (Consultant/Advisory Board, Honorarium, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received, Speaker/Honoraria includes speakers bureau, symposia, and expert witness)
Objective: Evaluate botulinum toxin A (BoNT-A) reinjection intervals within an integrated rehabilitation management setting.
Design: Prospective, observational study (NCT02454803) examining outcomes from repeated BoNT-A cycles over 2 years. Setting : International multicenter study in 53 secondary care centers in 14 countries. Participants : Adults (≥18 years) with upper limb spasticity of various etiology.
Interventions: Patients are treated with BoNT-A per routine practice.
Main Outcome Measures: The primary outcome is Goal Attainment Scaling. In this analysis, we report on the duration of injection intervals (presented for patients who did not switch between products during the study).
Results: Of the 1004 enrolled patients, 828 remained on the same BoNT-A product during the study and had their injection intervals assessed. The mean number of injection intervals was 3.8 ±1.7 for abobotulinumtoxinA (n=555), 4.3 ±2.3 for onabotulinumtoxinA (n=196), and 4.7 ±2.0 for incobotulinumtoxinA (n=77). Across the study, patients had raw mean ±SD [range] injection intervals of 222.8 ±167.2 [21–938], 203.9 ±174.1 [28–833], and 167.4 ±106.3 [60–703] days for abobotulinumtoxinA, onabotulinumtoxinA, and incobotulinumtoxinA, respectively. Conclusions: When designing patient treatment plans, clinicians must consider the individual characteristics of the various BoNT-A products, including dosing recommendations and the duration of symptom relief between injection sessions. These real-world injection data from a large, international observational study support the clinical experience that there are clinical differences between BoNT-A products that should be taken into account.
Level of Evidence: Level II
To cite this abstract in AMA style:Stokes LFT, Lysandropoulos A, Jacinto J, Ashford S, Fheodoroff K, Brashear A, Maisonobe P. Real-Life Data on the Time to Retreatment with Botulinum Toxin a in Upper Limb Spasticity Management [abstract]. PM R. 2020; 12(S1)(suppl 1). https://pmrjabstracts.org/abstract/real-life-data-on-the-time-to-retreatment-with-botulinum-toxin-a-in-upper-limb-spasticity-management/. Accessed September 24, 2023.
« Back to AAPM&R Annual Assembly 2020
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/real-life-data-on-the-time-to-retreatment-with-botulinum-toxin-a-in-upper-limb-spasticity-management/